Treats lepromatous leprosy, including dapsone-resistant lepromatous leprosy and…. Sold as Lamprene. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Clofazimine (sold as Lamprene), first approved Dec 15, 1986, with 0 new uses approved and 0 published complete response letters.
| Telacebec in Adults With Multibacillary Leprosy (TEBULA Leprosy Trial)Leprosy, Multibacillary · Fondation Raoul Follereau | Phase 2 | Not yet recruiting | Nov 5, 2026 |
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform TrialMycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection · The University of Queensland | Phase 2 | Not yet recruiting | Mar 20, 2026 |
| Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary InfectionNon-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection · Vancouver Coastal Health | Phase 1 | Enrolling by invitation | Nov 14, 2025 |
| 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei ProvinceTreat to Target, Treatment Duration · Wuhan Pulmonary Hospital | Not applicable | Not yet recruiting | Sep 30, 2025 |
| A Phase 2b Clinical Study of JDB0131 Benzenesulfonate TabletsTuberculosis, Multidrug Resistant Pulmonary Tuberculosis · WestVac Biopharma Co., Ltd. | Phase 2 | Recruiting | Sep 12, 2025 |
| A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant TuberculosisEfficacy and Safety · Wuhan Pulmonary Hospital | Not applicable | Not yet recruiting | Aug 17, 2025 |
| Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy PatientsLeprosy, Mycobacterium Leprae Infection · South Valley University | Not applicable | Recruiting | Feb 11, 2025 |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese CohortDrug-resistant Tuberculosis, Pulmonary Tuberculosis · Huashan Hospital | Phase 3 | Active, not recruiting | Oct 21, 2024 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Novartis